Truist Securities Maintains Hold on Fresenius Medical Care, Lowers Price Target to $24
Truist Securities analyst David Macdonald maintains Fresenius Medical Care (NYSE:FMS) with a Hold and lowers the price target from $25 to $24.
Share
Why It Matters
An expert reviewer still thinks Fresenius Medical Care is okay, not great. They lowered their expected price a tiny bit, which hints at caution ahead.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.